Paladin Labs Inc, a leading Canadian specialty pharmaceutical company, announced that its biotechnology division, ViRexx, has received a contribution from the National Research Council of Canada Industrial Research Assistance Programme (NRC-IRAP). This 14-month project will focus on the development of bio-nanoparticle-based siRNA therapeutic vaccines using Chimigen Vaccine Platform for Hepatitis B (HBV) and Hepatitis C (HCV) infections.

"We are pleased to be working with NRC to further develop this promising technology, and the financial support, in addition to both technical and business oriented advisory services, from NRC-IRAP will accelerate the development of ViRexx's proprietary Chimigen Platform for multiple uses in the field of infectious diseases," commented Dr Rajan George, the chief technology officer of ViRexx.

ViRexx is currently developing a Chimigen HBV Therapeutic Vaccine to address the 370 million chronic carriers of Hepatitis B virus worldwide, who are poorly served by existing therapies. ViRexx is also developing Chimigen HCV Therapeutic vaccines, as well as bio-nanoparticle-based siRNA therapeutic vaccines for both HBV and HCV infections.

"The acquisition of ViRexx gave us a very promising technology in Chimigen Platform. We are excited to be working with NRC-IRAP on the development of this important technology platform," added Jonathan Ross Goodman, president and CEO of Paladin Labs Inc.
Paladin Labs is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

ViRexx, a division of Paladin Labs Inc, develops innovative targeted therapeutics for individuals that suffer from infectious diseases and cancer.